patisiran
Selected indexed studies
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. (N Engl J Med, 2018) [PMID:29972753]
- Patisiran. (, 2012) [PMID:36689610]
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. (N Engl J Med, 2023) [PMID:37888916]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. (2018) pubmed
- Patisiran. (2012) pubmed
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. (2023) pubmed
- Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy. (2023) pubmed
- PMID:40892953 (2019) pubmed
- Patisiran: First Global Approval. (2018) pubmed
- Patisiran. (2026) pubmed
- Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. (2019) pubmed
- Patisiran for the treatment of patients with familial amyloid polyneuropathy. (2019) pubmed
- Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. (2019) pubmed